Revascularization in cardiogenic shock

[1]  H. Thiele,et al.  Frequency and Impact of Bleeding on Outcome in Patients With Cardiogenic Shock. , 2020, JACC. Cardiovascular interventions.

[2]  J. Messenger,et al.  Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. , 2020, JAMA.

[3]  S. Blankenberg,et al.  Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock: Matched-Pair IABP-SHOCK II Trial 30-Day Mortality Analysis , 2019, Circulation.

[4]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[5]  H. Thiele,et al.  One‐Year Outcomes after PCI Strategies in Cardiogenic Shock , 2018, The New England journal of medicine.

[6]  Ajay K. Jain,et al.  Contemporary trends in cardiogenic shock: Incidence, intra-aortic balloon pump utilisation and outcomes from the London Heart Attack Group , 2018, European heart journal. Acute cardiovascular care.

[7]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[8]  H. Wienbergen,et al.  Management and predictors of outcome in unselected patients with cardiogenic shock complicating acute ST-segment elevation myocardial infarction: results from the Bremen STEMI Registry , 2018, Clinical Research in Cardiology.

[9]  H. Thiele,et al.  Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials , 2017, European heart journal.

[10]  H. Thiele,et al.  PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock , 2017, The New England journal of medicine.

[11]  E. Ohman,et al.  Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association , 2017, Circulation.

[12]  G. Schuler,et al.  ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[13]  D. Brodie,et al.  Extracorporeal membrane oxygenation: evolving epidemiology and mortality , 2016, Intensive Care Medicine.

[14]  Sunil V. Rao,et al.  Impact of access site choice on outcomes of patients with cardiogenic shock undergoing percutaneous coronary intervention: A systematic review and meta-analysis. , 2015, American heart journal.

[15]  Sunil V. Rao,et al.  Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial , 2015, The Lancet.

[16]  E. Ohman,et al.  Management of cardiogenic shock. , 2015, European heart journal.

[17]  R. Abbate,et al.  Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. , 2015, Journal of the American College of Cardiology.

[18]  M. Hadamitzky,et al.  Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction , 2014, Thrombosis and Haemostasis.

[19]  G. Schuler,et al.  Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial , 2013, The Lancet.

[20]  Gregg W Stone,et al.  Effect of platelet inhibition with cangrelor during PCI on ischemic events. , 2013, The New England journal of medicine.

[21]  E. Romagnoli,et al.  Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study. , 2012, Journal of the American College of Cardiology.

[22]  G. Schuler,et al.  Intraaortic balloon support for myocardial infarction with cardiogenic shock. , 2012, The New England journal of medicine.

[23]  N. Danchin,et al.  Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French nationwide registries. , 2012, European heart journal.

[24]  P. Widimsky,et al.  Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study , 2011, Acute cardiac care.

[25]  Sunil V. Rao,et al.  Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial , 2011, The Lancet.

[26]  G. Chatellier,et al.  Shock in acute myocardial infarction: the Cape Horn for trials? , 2010, European heart journal.

[27]  R. Mehta,et al.  Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease? , 2010, American heart journal.

[28]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[29]  M. Pfisterer,et al.  Ten-Year Trends in the Incidence and Treatment of Cardiogenic Shock , 2008, Annals of Internal Medicine.

[30]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[31]  H. White,et al.  Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. , 2006, JAMA.

[32]  M. Pfisterer,et al.  Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry. , 2006, European heart journal.

[33]  D. Morrison,et al.  Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[34]  Sunil V. Rao,et al.  Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. , 2004, JAMA.

[35]  M. Gottwik,et al.  Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK). , 2004, European heart journal.

[36]  Samin K. Sharma,et al.  Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. , 2003, Journal of the American College of Cardiology.

[37]  J. Boura,et al.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .

[38]  D. Antoniucci,et al.  Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. , 2002, The American journal of cardiology.

[39]  Deepak L. Bhatt,et al.  Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. , 2002, The American journal of cardiology.

[40]  H. White,et al.  Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? , 2000, Journal of the American College of Cardiology.

[41]  H. White,et al.  Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. , 1999, The New England journal of medicine.